CRO Chiltern goes up on auction block

The global CRO Chiltern International has been put on the auction block, according to a report in The Mail on Sunday. The report says that Chiltern's private equity owners are looking for about £200 million, which would double what they paid for the company. Over the past year the CRO business has been going through a wave of mergers and acquisitions as the industry undergoes a major shakeout. That's created some quick profits for the groups that had been snapping up these companies. Chiltern conducts Phase I-IV studies in dozens of countries. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.